



SDI Review Form 1.6

Journal Name:	<u>Journal of Advances in Medical and Pharmaceutical Sciences</u>
Manuscript Number:	Ms_JAMPS_23349
Title of the Manuscript:	EVALUATION OF TOXICOLOGICAL EFFECTS OF ORAL ADMINISTRATION OF CADMIUM NITRATE ON LIVER OF ADULT WISTER RATS
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	The authors mentioned in the aim of the work "The present study was therefore designed to evaluate toxic effect of cadmium nitrate on liver of 64 adult wistar rats." -> <u>please give more clarification and more identified sentence about "toxic effect" as it may be enzymatic- LD50- Histological damage or immunological changes. This is very important to be more précised and to provide a good classification of your toxicological research.</u> <u>In methods:</u> <u>The authors mentioned "</u> Rats in group B, C, and D 78 (cadmium nitrate group) were given 300mg/kg/bw cadmium nitrate, 225mg/kg/bw of cadmium 79 nitrate and 150mg/kg/bw of cadmium nitrate administered orally through an orogastric cannula 80 into the stomach via the esophagus, once a day, " -> is it respectively, ie is group B dose 300 then group C 225 then group D 150 , if so please clarify why you did not start by 150 (B), then 225 (C) then 300 (D). The rule is to gradual increase the dose to obtain results based on a gradual increase	



SDI Review Form 1.6

	of the used or the tested material. Then you must mention, either from net research or from pilot study what is the LD 50 of your tested material as it is very important in any toxicological study to report it and to compare your toxic dose with the reported LD 50 in other research if any difference was found. <u>Also you mentioned "</u>All 81 aspects of these studies were conducted under the guideline of Nigeria Medical Ethical 82 Association for Accreditation of Laboratory Animal Care.- have therefore been performed in line with the ethical 217 procedure laid down in 1964 Declaration of Helsinki" → please complete this section by your own ethics committee approval of your protocol, it is mandatory in our research to place EC approval with your own source " agreement on your protocol" and number. You also mentioned "the rats were at the time of 85 sacrifice first weighed and then cervical dislocation was carried out." → you must give urethane to your rats before scarification "ethically" or please mention how did you do your scarification according to EC guidelines?????????? Please mention the manufacturer and the country	
--	---	--



SDI Review Form 1.6

	of origin of the "commercially available kit for AST & ALT measurements" Your duration is 21 days and you mentioned week I, II, III in your results as measurements of liver enzymes→ please make it one form either you mention in 3 weeks or 21 days then measurements accordingly either after 7,14,21 days or week 1,2,3 . This is the common forms to be used in expression of duration in research and please refer to journal guidelines in numerical form needed. Ethical issue: Yes, the own source of EC agreement and number need to be mentioned	
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		

Reviewer Details:

Name:	Sahar Mohamed Kamal Shams El Dine
Department, University & Country	Pharmacology dept, Ain Shams University, Cairo, Egypt